About Hemotune
Hemotune is a company based in Zurich (Switzerland) founded in 2017 by Lukas Langenegger and Carlos Andrea Mora.. Hemotune has raised $28.86 million across 7 funding rounds from investors including Zurcher Kantonalbank, EIT Health and Hemex Health. Hemotune offers products and services including Blood Purification Platform and HemoSystem. Hemotune operates in a competitive market with competitors including Outset Medical, Fresenius, Medcura, ExThera Medical and Diality, among others.
- Headquarter Zurich, Switzerland
- Founders Lukas Langenegger, Carlos Andrea Mora
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Hemotune Ag
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$28.86 M (USD)
in 7 rounds
-
Latest Funding Round
$15.6 M (USD), Series B
Mar 25, 2024
-
Investors
Zurcher Kantonalbank
& 10 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hemotune
Hemotune offers a comprehensive portfolio of products and services, including Blood Purification Platform and HemoSystem. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform using magnetic beads for purifying blood in septic shock cases.
System for multi-target blood purification to enhance patient outcomes.
Unlock access to complete
Funding Insights of Hemotune
Hemotune has successfully raised a total of $28.86M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $15.6 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series B — $15.6M
-
First Round
First Round
(01 Jun 2017)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2024 | Amount | Series B - Hemotune | Valuation | HEMEX , EFI Lake Geneva Ventures | |
| Apr, 2022 | Amount | Series B - Hemotune | Valuation | OCCIDENT – The Science Investor. | |
| Jul, 2020 | Amount | Series A - Hemotune | Valuation | OCCIDENT – The Science Investor. |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Hemotune
Hemotune has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Zurcher Kantonalbank, EIT Health and Hemex Health. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A Zurich-based VC firm focused on early-stage life science companies.
|
Founded Year | Domain | Location | |
|
Regulatory affairs and marketing services are provided for healthcare entities.
|
Founded Year | Domain | Location | |
|
Venture capital investments are provided to deep-tech startups.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Hemotune
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Hemotune
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Hemotune Comparisons
Competitors of Hemotune
Hemotune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Outset Medical, Fresenius, Medcura, ExThera Medical and Diality, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Hemodialysis machines with touchscreen displays are provided for medical use.
|
|
| domain | founded_year | HQ Location |
System-critical products and services for healthcare therapies are provided.
|
|
| domain | founded_year | HQ Location |
Developer of the device for controlling bleeding
|
|
| domain | founded_year | HQ Location |
Medical devices for the rapid treatment of bloodstream infections and pathogen-reduction in blood banking
|
|
| domain | founded_year | HQ Location |
Developer of portable hemodialysis device
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Hemotune
Frequently Asked Questions about Hemotune
When was Hemotune founded?
Hemotune was founded in 2017.
Where is Hemotune located?
Hemotune is headquartered in Zurich, Switzerland.
Who is the current CEO of Hemotune?
Lukas Langenegger is the current CEO of Hemotune. They have also founded this company.
Is Hemotune a funded company?
Hemotune is a funded company, having raised a total of $28.86M across 7 funding rounds to date. The company's 1st funding round was a Series A of $5.57M, raised on Jun 01, 2017.
What does Hemotune do?
Hemotune was founded in 2017 in Zurich, Switzerland, within the medtech sector. A platform for blood purification is being developed, utilizing magnetic beads to restore immune balance in patients with septic shock. Operations focus on improving outcomes through this technology, with development centered in Switzerland. Key personnel include co-founders Lukas Langenegger as CEO and Carlos Andrea Mora.
Who are the top competitors of Hemotune?
Hemotune's top competitors include Outset Medical, Fresenius and Diality.
What products or services does Hemotune offer?
Hemotune offers Blood Purification Platform and HemoSystem.
Who are Hemotune's investors?
Hemotune has 11 investors. Key investors include Zurcher Kantonalbank, EIT Health, Hemex Health, European Union, and Green Cross Medical Systems.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.